|
WO2021047616A1
|
|
Oxynitride heterocyclic heptane-based spiro compound, intermediate and preparation method therefor
|
|
WO2021018240A1
|
|
Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
WO2021018195A1
|
|
Novel tricyclic compounds as bcr-abl inhibitors
|
|
WO2021018194A1
|
|
Heterocyclic compounds as bcr-abl inhibitors
|
|
WO2021018032A1
|
|
Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
|
|
WO2021013028A1
|
|
Pharmaceutical combination and use thereof
|
|
EP3814358A1
|
|
Method for preparing 2-indolinospirone compound and intermediate thereof
|
|
WO2021000899A1
|
|
A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
|
|
WO2020259553A1
|
|
Combination of fak inhibitor and btk inhibitor for treating a disease
|
|
WO2020228695A1
|
|
Method and composition for predicting efficacy of bcl-2/bcl-xl inhibitors on cancer
|
|
US2020297743A1
|
|
Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
|
|
EP3814525A1
|
|
Treatment methods and biomarkers for mdm2 inhibitors
|
|
TW202043241A
|
|
Macrocyclic fused pyrrazoles as mcl-1 inhibitors
|
|
TW202043238A
|
|
Macrocyclic spiroethers as mcl-1 inhibitors
|
|
TW202039430A
|
|
Method for preparing sulfonamides
|
|
TW202039467A
|
|
Process for preparing sulfonamide compounds
|
|
WO2020135647A1
|
|
Pharmaceutical composition and preparation method thereof
|
|
KR20210003178A
|
|
Compounds for treating osteoarthritis
|
|
AU2019394218A1
|
|
Methods for cancer therapy
|
|
AU2019385458A1
|
|
Pharmaceutical composition and use thereof
|
